Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.

Lee JH, Choi SJ, Lee JH, Lee YS, Seol M, Ryu SG, Jang S, Park CJ, Chi HS, Lee JS, Kim WK, Lee KH

Department of Internal Medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul 138-736, South Korea. jhlee@amc.seoul.kr

For refractory and early relapsed AML, this prospective phase II clinical trial evaluated a salvage chemotherapy regimen, which was consisted of continuous infusion intermediate-dose cytarabine (1g/m(2)/day, 24h i.v. infusion x 5), mitoxantrone (12 mg/m(2)/day x 3), and etoposide (150 mg/m(2)/day x 3). We treated 33 patients and 17 (51.5%) achieved CR with a median duration of 117 days. Median overall survival was 219 days. Our results suggest that continuous infusion intermediate-dose cytarabine, together with mitoxantrone and etoposide, may induce CR in a significant proportion of patients with refractory or early relapsed AML, although remission duration was short.

Published 12 December 2005 in Leuk Res, 30(2): 204-10.
Full-text of this article is available online (may require subscription).

© 2004-2008 Acute Myeloid Leukemia Research Today. All Rights Reserved.